Literature DB >> 7760988

Multicentric double-blind study comparing efficacy and safety of minaprine and imipramine in dysthymic disorders.

E Salzmann1, J L Robin.   

Abstract

This multicentre study compares the therapeutic efficacy and safety of minaprine (200 mg) to that of imipramine (50, 75, 100 mg) in the treatment of patients over 40 years suffering from dysthymic disorders as diagnosed according to DSM III. After 4-7 days on placebo, 67 patients were randomly assigned to receive either drug for a period of 6 weeks in a double-blind manner. As rated by the Hamilton Depression Rating Scale and evaluated by exploratory statistics, minaprine showed similar efficacy to imipramine in these patients. Minaprine was better tolerated than imipramine according to the physicians' tolerance rating (p < 0.05) and produced significantly fewer symptoms of the autonomic nervous system as compared to imipramine (p < 0.01).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7760988     DOI: 10.1159/000119175

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  4 in total

1.  Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation.

Authors:  Jeffrey M Craft; Linda J Van Eldik; Magdalena Zasadzki; Wenhui Hu; D Martin Watterson
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 2.  A comparison of active drugs for the treatment of dysthymia.

Authors:  M Silva de Lima; M Hotopf
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 3.  Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence.

Authors:  Maurício S De Lima; Matthew Hotopf
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings.

Authors:  Boadie W Dunlop; Jaclyn Gray; Mark H Rapaport
Journal:  Behav Sci (Basel)       Date:  2017-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.